CLEC-2 is a C-type lectin-like receptor with the prominent involvement in platelet activation, which was increased in coronary heart disease (CHD) and acute ischemic stroke (AIS) and was associated with stroke progression and stroke prognosis. Here, we aimed to examine the prognostic value of CLEC-2 in death and vascular events recurrence in acute ischemic stroke patients. 352 patients with AIS were prospectively studied. All patients were followed up for 1 year. Death for all vascular events and a combination of death and vascular diseases (recurrent stroke, myocardial infarction, hospitalized and treated angina, hospitalized and treated peripheral arterial disease) was recorded. During 1 year of follow-up, 46 patients (14.2%) experienced death or combined endpoints (23 death and 46 combined endpoints). Plasma CLEC-2(pCLEC-2) was significantly associated with an increased risk of death and combined events of death and vascular diseases after adjusting for age, sex, history of hypertension, diabetes mellitus and CAD, and NIHSS scores. Each 1-SD higher log-transformed pCLEC-2 was associated with a 4.27(HR 4.27, 95%CI 1.71-10.65) fold increased risk for death and a 2.42 fold increased risk for combined endpoints (HR 2.42, 95%CI 1.52-3.86). The optimal cut-off point of pCLEC-2 for predicting death was 184.38pg/ml. Higher pCLEC-2 levels at admission were associated with increased risk of death and combined events of death and vascular diseases in patients with AIS, which indicated pCLEC-2 an important prognostic factor for AIS. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.